

Financial Results for the First Quarter of FY2011

Sawai Pharmaceutical Co., Ltd.

Code 4555, First Section of the TSE

August 9, 2011

Overview of the Financial Results for the 1Q of FY2011

- Compared with the 1Q of FY2010 results which was significantly boosted up by the revision of the additional fee system for generic drugs, Net Sales in 1Q of FY 2011 results increase slightly, due to the Great East Japan earthquake
- Operating income slightly decreases, however Sawai keeps operating margin above 20%

Ordinary income and net income increase

(Unit: Millions of yen, %)

	FY2010 1Q		FY2011 1Q	Year on Year		
	Millions of yen	/Sales (%)	Millions of yen	/Sales (%)	Mil. yen	Growth (%)
Net Sales	15,792	100.0%	15,878	100.0%	86	0.5%
Operating Income	3,489	22.1%	3,382	21.3%	-107	-3.1%
Ordinary Income	3,443	21.8%	3,522	22.2%	79	2.3%
Net Income	1,914	12.1%	2,238	14.1%	324	17.0%

Copyright © 2011 Sawai Pharmaceutical Co., Ltd. All Rights Reserved.

Sales per Medical Institution Types

- Total results of delivery to Medical Institutions increase approximately 10% (value basis)
 - Among them, delivery to Pharmacies steadily increases approximately 14% (value basis)

The Track Record of SAWAI's Products Delivered to Medical Institutions

	a) Nationwide	FY2010 1Q		-	FY2011 1Q	Year on Year		
Institution Type	Total Number	Number of Customers	Sales Share	b) Number of Customers	b/a (Coverage Rate)	Sales Share	Changes in Number of Customers	Sales Growth
Hospital	8,742	6,927	16.7%	7,062	80.8%	16.5%	135	8.4%
DPC Hospital	1,449	1,316	8.0%	1,331	91.9%	8.2%	15	12.6%
Clinic	103,000	26,678	23.3%	26,770	26.0%	21.2%	92	0.1%
Pharmacy	81,500	45,708	59.5%	47,363	58.1%	61.7%	1,655	13.9%
Dispensing Pharmacy	55,600	45,347	58.7%	47,032	84.6%	61.0%	1,685	14.1%
Drug stores, etc.	25,900	361	0.8%	331	1.3%	0.7%	-30	-1.2%
Others	-	-	0.5%	-	-	0.6%	-	24.2%
Total	193,242	79,313	100.0%	81,195	(42.0%)	100.0%	1,882	9.8%


by Distribution Companies

DPC, Diagnosis Procedure Combination, means fixed payment system for inpatients

Sales by Distribution Channels


Sales through wholesalers increase, however sales through agencies slightly decrease

Sales ratio through wholesalers relatively increase



Sales by Listed Year of Drugs

Drugs listed after FY2009 grow steadily



	FY2010 1Q	FY2011 1Q	Y on Y	Rate of achievement	
	Mil. yen Mil. yen		Growth	acine tentent	
Listed in FY2011	-	90	-	4.5%	
Listed in FY2010	35	322	816.7%	14.6%	
Listed in FY2009	2,013	2,362	17.3%	20.5%	
Listed in FY2008	1,127	1,071	-4.9%	19.8%	
Listed in FY2007	1,123	1,114	-0.8%	22.7%	
Listed in FY2006	1,430	1,452	1.6%	23.0%	
Listed in FY2005	2,037	1,750	-14.1%	21.9%	
Listed in FY2004	759	774	2.0%	21.5%	
Listed in FY2003	962	923	-4.0%	24.3%	
Transferred Drug, etc.	368	314	-14.8%	24.2%	
Existing Drugs	5,933	5,701	-3.9%	24.3%	
Total	15,792	15,878	0.5%	21.9%	

Comparison of Sales Volume

Compared with the FY2010 1Q results, sales volume decreases and sales amount increases slightly in FY2011 1Q results
Other metabolic drugs are the major factor of sales volume decrease

The rapeutic Category	Volume composition (FY2010 1Q)	Volume composition (FY2011 1Q)	Y on Y (volume)	Y on Y (value)
Gastro-intestinal drugs	23.6%	24.4%	1.0%	7.1%
Cardiovascular drugs	22.3%	22.3%	-2.7%	-1.2%
Central nervous system drugs	13.0%	12.6%	-5.3%	-2.9%
Other metabolic drugs	12.1%	10.4%	-15.8%	-9.3%
Vitamins	8.1%	8.6%	3.7%	1.5%
Blood/body fluid pharmaceutical products	5.1%	5.3%	1.2%	0.8%
Antibiotics	2.6%	2.5%	-4.0%	-4.7%
Antiallergic drugs	1.8%	1.9%	5.6%	11.3%
Chemotherapeutic drugs	0.7%	0.7%	-6.1%	-3.5%
Others	10.8%	11.3%	1.6%	7.0%
Total	100.0%	100.0%	-2.5%	0.5%

Analysis of Income Statements

	(Unit: Millions of yen, %)						Major Factors of	
	FY2(1(FY2 1(Year o	n Year		YOY Changes
	Mil. yen	/Sales (%)	Mil. yen	/Sales (%)	Mil. yen	Growth (%)		(Unit: Millions of yen)
Net Sales	15,792	100.0%	15,878	100.0%	86	0.5%		Variable cost ratio
Cost of Sales	8,469	53.6%	8,214	51.7%	-255	-3.0%		(3.3% improve) : +500
Gross Profit	7,323	46.4%	7,664	48.3%	341	4.7%	┦└	• Fixed cost increase : - 200
SG&A Expenses	3,833	24.3%	4,282	27.0%	448	11.7%		
Operating Income	3,489	22.1%	3,382	21.3%	-107	-3.1%		 Personnel Cost : +100 R&D Expenses : +100
Non-operating Income and Expenses	-46	-0.3%	140	0.9%	186			• Others : + 200
Ordinary Income	3,443	21.8%	3,522	22.2%	79	2.3%		
Extraordinary Gain and Loss	-56	-0.3%	-5	0.0%	51			
Income Taxes and Enterprise Taxes, Minority Interests, etc.	1,472	9.3%	1,278	8.1%	-193			
Net Income	1,914	12.1%	2,238	14.1%	324	17.0%		

FY2011 Earnings Forecasts

 Although sales progress is slow, performance after 2Q is expected to recover.

Set earnings forecast unchanged

(Unit: Millions of yen, %)

	FY20 1	11	FY2011 Full Year (Forecast)				
	<u>1Q</u>						
	Mil. yen /Sales (%)		Mil. yen	/Sales (%)	Rate of Achievement		
Net Sales	15,878	100.0%	72,500	100.0%	21.9%		
Cost of Sales	8,214	51.7%	38,200	52.7%	21.5%		
Gross Profit	7,664	48.3%	34,300	47.3%	22.3%		
SG&A Expenses	4,282	27.0%	19,800	27.3%	21.6%		
Operating Income	3,382	21.3%	14,500	20.0%	23.3%		
Ordinary Income	3,522	22.2%	14,400	19.9%	24.5%		
Net Income	2,238	14.1%	8,300	11.4%	27.0%		

Disclaimer

- The plans, forecasts, strategies and other information regarding the Sawai group contained in this presentation involve certain risks and uncertainties, except for historical facts. Therefore, there is no guarantee as to the accuracy of this information.
- Risks and uncertainties may include, but are not limited to, the economic environment for prescription drugs, which is the main operating domain of the Sawai group, market competition and services offered by the Group.

Contact Information

Corporate Planning & IR Group Sawai Pharmaceutical Co., Ltd. E-mail: **ir@sawai.co.jp**